NurExone Biologic

EV-based Drug Platform to Treat Damage in the Central Nerve System

Health Tech & Life Sciences
Public on TSXV on Jul 2022

Company Overview

Snapshot

Founded in January 2020, NurExone Biologic operates with 11–50 employees and has raised a total of $9.53 million across 8 funding rounds. The company went public on TSXV in July 2022, marking a significant milestone in its development.

Business overview

NurExone Biologic is a Health Tech & Life Sciences company focused on revolutionizing recovery from central nervous system injuries. The company develops a biological extracellular vesicles-based technology drug platform designed to regenerate and rewire neurons. Its core product, ExoPTEN, utilizes intranasal exosome administration to treat conditions like spinal cord injury, offering an alternative to existing treatments. NurExone operates within the Pharmaceuticals and Drugs Discovery & Development sectors, targeting the broader healthcare and life sciences markets.

Strategic signal

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing process, which strengthens its supply chain readiness. This patent signals to investors a significant step towards commercialization and scalability, indicating the company's progress in establishing robust infrastructure for its therapeutic platform.

Company Intelligence Q&A

What was a key regulatory achievement for NurExone Biologic in late 2023?
In October 2023, NurExone Biologic received FDA Orphan-Drug Designation for its ExoPTEN therapy, aimed at treating acute spinal cord injury. This designation is expected to accelerate the development pathway for the drug.
What strategic move did NurExone Biologic make regarding its European market access?
In November 2024, NurExone Biologic secured EMA Orphan Status for ExoPTEN in spinal cord injury, which is intended to accelerate its pathway to European markets.
What progress has NurExone Biologic made in preclinical studies for spinal cord injury treatment?
In September 2024, NurExone demonstrated an extended therapeutic window for ExoPTEN post spinal-cord injury in a preclinical study, indicating potential for broader clinical application.
What recent patent was granted to NurExone Biologic?
In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing, which is expected to strengthen its supply chain readiness.
What was a significant corporate update for NurExone Biologic in November 2025?
In November 2025, NurExone Biologic announced its third-quarter 2025 financial results and provided a corporate update, including securing over C$3.18 million through accelerated warrant exercises.

External links